420 with CNW — Study Links Marijuana Use to Improved Quality, Frequency of Sex

A recent scientific assessment of scholarly studies on human sexuality and cannabis has found that there is a complex link between sex and cannabis use. However, the general consensus is that cannabis tends to increase the frequency, enjoyment and desire for sex.

The review, published in the “Psychopharmacology Journal,” suggests that higher amounts of cannabis may impair performance and desire, while smaller doses may be more favorable to sexual fulfillment. The effects also appear to vary based on gender.

The study’s authors noted that marijuana can improve intimacy with partners, reduce shame and anxiety, lessen inhibitions and increase sexual pleasure. The authors also observed enhanced sensory sensations during sex and greater enjoyment during masturbation, suggesting that cannabis has a major effect on sex experiences.

The review emphasizes that sex is influenced by a variety of emotional and physical factors, and cannabis affects people in a holistic way that can influence both the emotional and physical aspects of sexual experiences.

Though there is limited study on women’s experiences, women appear to gain more from cannabis use in terms of its sexual effects than men do. The authors noted that low dosages of hypnotic cannabinoids and sedatives, such as THCV and THC, may lessen sexual activity anxiety, which may increase arousal and desire for sexual activity, particularly in women.

For men, findings are mixed, with some studies indicating that marijuana use can lead to premature and delayed ejaculation as well as erectile dysfunction, while others suggest the opposite.

Dosage and frequency of marijuana use are key factors, although more research is needed. Higher sexual function seems to be associated, at least generally, with regular cannabis use. A survey cited in the review found that women who used cannabis more frequently performed better than those who did so infrequently on tests of female sexual function.

Increased cannabis use frequency correlated with better overall FSFI scores and improvements in orgasm, desire, satisfaction domains, arousal and orgasm. Higher frequency categories also saw a decline in reports of sexual dysfunction. According to one study, women who used cannabis regularly were twice as likely as infrequent users to report having satisfying orgasms.

Men who regularly use cannabis have been linked to orgasm-related issues, such as early or delayed ejaculation. However, another study found no link between the frequency of cannabis usage and problems maintaining an erection.

Given the varied and occasionally contradictory results, the researchers have advocated for additional studies to account for other variables. The authors noted that cannabis has a varied impact on human sexuality, including both negative and positive. They emphasized the need for additional study to understand how marijuana affects sexuality, as doing so may lessen harm and even enhance human experiences.

With the insights so far gleaned, consumers can be assured that moderately using various marijuana products from the hundreds of licensed companies such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) could be beneficial to their well-being without triggering notable adverse events.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Shows Partner Violence Decreases After Marijuana Legalization

A recent study found that the legalization of recreational cannabis significantly reduces intimate partner violence (IPV). The research highlights that legal recreational marijuana affects the link between heavy alcohol consumption and IPV, likely because people are choosing cannabis over alcohol.

The study was written by Georgetown University master student Samantha Gene Baldwin, who described the findings as surprising.

“Given that cannabis use is an established IPV-risk factor, and that legalization typically leads to increased usage, one might expect RML to elevate IPV rates,” Baldwin explained. “RML may lessen its negative effects on IPV, though, if marijuana takes the place of alcohol, which is more likely to cause IPV.”

Baldwin’s research used data from the FBI’s National Incident-Based Reporting System (NIBRS) spanning from 2013 to 2019, excluding the COVID-19 pandemic period. The analysis revealed that the legalization of adult-use cannabis led to 56.6 fewer reported IPV incidents per 100,000 individuals.

Despite previous studies linking cannabis and substance use with higher IPV rates, Baldwin pointed out that the replacement of alcohol with marijuana, which is less strongly associated with IPV, resulted in an overall reduction in violence.

Historical cannabis prohibition may also have influenced trends. Baldwin suggested that when marijuana was illegal, its users might have been more prone to impulsive and risky behaviors. This context provides a different perspective on the implications of legalization.

Interestingly, the study found that in states without legal marijuana, IPV rates decreased as the number of heavy drinkers increased. Baldwin stated that lower rates of IPV are correlated with higher rates of excessive drinking in states where marijuana use is not permitted for recreational purposes. In particular, there were 5.6 fewer IPV instances for every percentage point increase in heavy drinkers.

On the other hand, eight additional IPV instances occurred for every percentage point rise in heavy drinkers in states with RML.

Baldwin’s thesis emphasizes the need for further research on state-specific trends and the impact of retail marijuana accessibility on violence. “Future studies should examine how different cannabis policies, ranging from full illegality to decriminalization, medical cannabis legalization and RML, affect IPV,” Baldwin noted.

Previous research has also suggested a decline in domestic violence with cannabis legalization. For instance, a 2019 study found that states reducing penalties for simple marijuana possession saw a marked drop in domestic violence incidents resulting in serious injuries. Moreover, another study in 2021 concluded that the reduction in overall crime following cannabis legalization was significantly underestimated due to inconsistencies in FBI data and voluntary participation by local agencies.

These studies suggest that there are more benefits to cannabis legalization and allowing licensed companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) to operate. As more research is done, those less-than-obvious benefits could increasingly come to light.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW – Advocates Submit Petitions Seeking to Put Adult-Use Cannabis on Ballot in North Dakota

The organizers of a new ballot initiative in North Dakota to legalize recreational cannabis submitted their petition signatures on July 5, 2024. This step sets the stage for another potential statewide vote on a matter that voters and state lawmakers have previously turned down.

Steve Bakken, chair of the sponsoring committee for the New Economic Frontier measure, announced that the group had submitted more than 22,000 signatures. For the initiative to make it onto the November ballot, 15,582 of those signatures need to be valid. The Secretary of State’s office, led by Michael Howe, has until Aug. 12, 2024, to verify the signatures.

The move, according to Bakken, a former mayor of Bismarck and commissioner for Burleigh County, is intended to avert possible mismanagement by outside interests.

The proposed 20-page measure would allow adults aged 21 years of age and older to use recreational cannabis in their homes or on private property. It includes detailed regulations on processing and production, prohibited uses (such as in public vehicles or spaces), and permits for home cultivation.

The measure sets limits on the amount of cannabis that can be purchased and possessed: up to an ounce of flowers or dried leaves, 4 grams of concentrated cannabis oil, 1,500 mg of THC overall in items made from cannabis, and 300mg of edibles. It also allows for various cannabis products, including capsules, solutions, transdermal patches, topicals and concentrates.

In North Dakota, using marijuana under the age of 21 is a minor misdemeanor. While recreational use by adults isn’t a crime, possession is, with penalties ranging from infractions to misdemeanors based on the amount. Delivering cannabis is a felony, with increased penalties for factors such as proximity to schools.

Last year, according to data from the state’s courts, 4,451 people were charged with marijuana use or possession across the state.

Voters in the state rejected similar legalization measures in 2018 and 2022. In 2021, the state’s GOP-led House passed measures to legalize recreational cannabis, but these measures were defeated in the Republican-majority Senate. Opponents cited concerns over the negative societal and physiological effects of cannabis.

Voters did approve medical cannabis in 2016, and the state’s program now has nearly 10,000 active patients. A new procedure to facilitate pardons for minor marijuana offenses was adopted in 2019, with Governor Doug Burgum granting 100 pardons since then.

Currently, 24 states have legalized recreational cannabis, with Ohio being the most recent, having done so by initiative in last November. In addition legalization initiatives will be on the ballot in South Dakota and Florida this November. Additionally, in May, the federal government began steps to reclassify cannabis as a less harmful substance.

If North Dakotans finally pass this measure, market opportunities could open up for various companies such a Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) that may be looking to expand their footprint around the country.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Issuance of Three New Patents, Growing Portfolio to 46 Granted Patents Worldwide

Considered intangible assets, patents offer a significant competitive advantage and value for companies
Lexaria Bioscience views its growing patent portfolio as a solid foundation upon which to build future commercial partnerships
The company recently announced the receipt of three new patents in the E.U., Canada, and the U.S.
The issuance of the latest three patents grows Lexaria’s patent portfolio to 46 granted patents worldwide

Lexaria’s multi-patented DehydraTECH(TM) “drug delivery platform technology” offers proven increased bioavailability, enhancing the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of APIs. Strong patents covering this important technology are a critical factor for Lexaria.

A robust patent portfolio has always been a metric that investors use to judge a biotechnology or biopharmaceutical company. “A strong patent position is not only an important goal for a successful biotechnology business but also the primary asset by which a company will be valued during all stages of its development. Therefore, a patent portfolio must be as well designed and solidly constructed from the outset as all other aspects of the business,” a 2001 article conveyed (https://cnw.fm/1mIaw).

Not much has changed since the article’s publication, with a recent Forbes write-up observing that intangible assets, which include trade secrets, proficiency and expertise, trademarks, copyrights, and patents, accounted for 90% of the S&P 500’s total assets in 2020. This is a substantial increase from 1975’s figures, when intangible assets only accounted for 17% of the total assets, while tangible assets comprised the balance. The article noted that the explosion of intangible assets shows “that there is value to companies’ intellectual property (“IP”),” with patents holding the potential to be “far more valuable than physical assets” because they can offer businesses a competitive advantage (https://cnw.fm/vd9Au).

For its part, Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, looks at the value of its growing patent portfolio not only from a commercialization perspective but also from an IP protection standpoint. As CEO Chris Bunka put it in his 2024 letter to shareholders, “Those patents, when granted, can form the foundation upon which future commercial relationships are built” (https://cnw.fm/uBi8c).

The company recently received three new patents in the European Union (“E.U.”), Canada, and the United States (https://cnw.fm/WII23). In the EU, Lexaria received a newly granted patent in its patent family #6: Transdermal and/or Dermal Delivery of Lipophilic Active Agents. This patent is validated in Austria, the Czech Republic, France, the U.K., Germany, Italy, Poland, Spain, Sweden, and Switzerland. It is the company’s second patent in this family, following receipt of the first patent in Canada.

In Canada, Lexaria received a new patent granted in patent family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. It is the company’s fourth granted patent in this patent family and follows the receipt of a patent-granted status in the U.S., Australia, and Japan. Across the border in the U.S., Lexaria received its fourth granted U.S. patent in the patent family #24: Compositions and Methods for Treating Epilepsy.

The latter two patents granted in Canada and the U.S. build on the company’s research development initiatives and safeguard discoveries thereof. In 2021, Lexaria conducted research under its antiviral drug program, evidencing its patented DehydraTECH(TM) technology increased the delivery of five compounds from three antiviral classes into the bloodstream. The studies found that the drug-delivery improvement rates ranged between 42% and 204% (https://cnw.fm/DYgMn).

In addition, Lexaria in 2022 completed an animal seizure study that demonstrated that DehydraTECH-processed cannabidiol (“CBD”) resulted in enhanced seizure-inhibiting performance compared to Epidiolex(R), one of the world’s leading anti-seizure drugs. According to the company, the study’s results demonstrated the ability of DehydraTECH-CBD to reduce or eliminate seizure activity in animals and to, in some instances, even surpass the performance of Epidiolex (https://cnw.fm/EZw0Y).

The issuance of the latest three patents grows Lexaria’s patent portfolio to 46 granted patents worldwide. The company nonetheless continues to expect additional patents to be awarded in the future, given that it retains many valid patent applications throughout the world.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Tax Exemptions That Companies Could Access Once Cannabis Rescheduling Is Complete

The marijuana industry has been significantly hindered by Section 280E of the IRS Code, which prevents businesses dealing with substances listed in Schedules 1 and 2 of the Controlled Substances Act (CSA) from deducting regular business expenses.

Although Section 280E affects federal deductions, the regulations are not governed by federal laws in half of the markets where marijuana businesses are licensed to sell the drug for recreational or medical purposes. This implies that when cannabis businesses submit their state taxes, they are not subject to Section 280E.

This provision has stunted the growth of legal cannabis businesses across the country. However, the sector is about to undergo a major financial shift due to the Biden administration’s proposal to reclassify the drug from Schedule 1 to 3.

Cannabis enterprises are subject to significant limitations on their income-tax obligations and tax filings under Schedule 1. They must also consider whether the states in which they conduct business adhere to federal tax rules.

Section 280E prevents companies from claiming a wide range of administrative, selling and general expenses that are typical for other businesses, including the following:

Rent: Leasing space, a common deductible expense in other industries, cannot be deducted in the marijuana sector.
Salaries and wages: Paying employees, from executives to budtenders, does not provide any tax relief.
Utility costs: Essential utilities such as water and electricity cannot reduce the tax burden.
Maintenance and repairs: Keeping facilities in good condition is a nondeductible expense, limiting reinvestment and improvements.
Advertising and marketing: Promoting and building a brand drains funds without the benefit of tax write-offs.
Health insurance: Providing medical coverage for employees is an unrecognized expense, affecting workforce stability.
Amortization and depreciation: The gradual loss of asset value over time is not acknowledged by federal tax rules for nonplant-touching assets.

What could change if cannabis businesses were freed from the constraints of Section 280E? It would result in a scenario where the industry is no longer categorized alongside substances such as LSD and heroin but rather with everyday prescription medications.

For starters, cannabis businesses could claim deductions for typical expenses such as salaries, rent, utility bills, and advertising and marketing costs. Money saved from 280E could be reinvested into the enterprise, spurring growth, job creation, research and development.

Further, cost savings could be passed on to consumers, making medical marijuana more affordable and accessible. Additionally, with reduced stigma, obtaining loans, credit lines and banking services could become easier. Relief could also lead to competitive pricing for patients and consumers, reducing the appeal of the black market.

The potential for these changes has the industry excited and speculative. Will these possible deductions create a thriving economic environment for marijuana businesses, or will financial parity with other industries remain elusive?

One thing is certain: rescheduling cannabis and making Section 280E irrelevant for marijuana entities could unleash a flood of prosperity and turn a once-restricted sector into a major player in the financial world.

The question: when will the industry be able to reach its full potential financially? Marijuana companies such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) can only wait for the final rule to be published so that they ascertain how the change in policy will impact their tax obligations.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 Expo Consumer Cannabis Convention In NJ To Draw over 15,000 Enthusiasts

The third annual 420 Expo Cannabis Convention will be held Sept 13-15, 2024 at the New Jersey Convention & Exposition Center. The event is expected to bring over 15,000 cannabis enthusiasts together for three days of networking with cannabis industry traders from all over the country. In addition, the convention will feature seminars, panel discussions, food, music, after parties, and exciting giveaways.

The event will also showcase a first-of-its-kind contest for licensed cultivators across the Garden State to compete for the 420 Expo Cannabis Cup until Sunday, July 28. In addition, B-Real, lead rapper of the multi-platinum hip-hop group Cypress Hill, will be gracing the event as guest of honor.

420 Expo is a well-organized event, curated by a team of enthusiastic professionals with significant cannabis industry experience, encouraging the local cannabis community by bringing together investors, young and veteran cannabis vendors, creatives, and enthusiasts, on a dynamic common forum.

New Jersey became the fourteenth state to legalize marijuana completely, on February 22nd, 2021. Atlantic City has a flourishing cannabis market waiting to get tapped by industry experts. The 420 Expo will bring tremendous business and collaboration opportunities to the New Jersey cannabis community.

The 420 Expo offers an interactive forum for new cultivators to exhibit their products before cannabis traders, connoisseurs, and enthusiasts. More than 100 vendors covering dispensaries, CBD traders, food, clothing, art and more will be setting up display booths.

Experts will shed light on topics such as selecting the right cannabis strains, legal expungement, cannabis to help addiction and recovery, investments, and more, at the roundtables and discussion panels. The expo seminar will spotlight topics such as medical marijuana, networking in cannabis, social equity, legal rights, cooking with cannabis, and more.

Tickets for 420 Expo are now available for general admission, VIP access, and bucket list smoke sessions.

To learn more please visit https://cnw.fm/Cu5yY

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Software Effective Solutions Corp. (SFWJ) Strengthening Cannabis Foothold as CSA Status Set to Change

An overwhelming share of U.S. adults say marijuana should be legal for medical or recreational use, reports Pew Research Center
The U.S. attorney general has submitted official notice to begin the process of moving marijuana from a Schedule 1 to Schedule 3 drug under the Controlled Substances Act
MedCana is committed to building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts

With a significant majority of Americans supporting cannabis use and the U.S. government on the verge of changing the status of the substance under the Controlled Substances Act (“CSA”), Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) is positioning itself for marked growth and success in the coming months. The company’s goal is to be the world’s premier resource for pharmaceutical cannabis products.

“As more states pass laws legalizing marijuana for recreational use, Americans continue to favor legalization of both medical and recreational use of the drug,” revealed a recent Pew Research Center survey (https://cnw.fm/fCQAD). “An overwhelming share of U.S. adults (88%) say marijuana should be legal for medical or recreational use.

“Nearly six in ten Americans (57%) say that marijuana should be legal for medical and recreational purposes, while roughly a third (32%) say that marijuana should be legal for medical use only,” the report continued. “Just 11% of Americans say that the drug should not be legal at all.”

After many years, the federal government is seemingly catching up to public opinion. In May the Justice Department announced that the attorney general had submitted official notice to begin the process of considering moving marijuana from a Schedule 1 to Schedule 3 drug under the CSA (https://cnw.fm/xHGvC).

“Marijuana has been classified as a Schedule 1 drug since Congress enacted the CSA in 1970,” the announcement noted. “On Oct. 6, 2022, President Biden asked the attorney general and the secretary of Health and Human Services (‘HHS’) to launch a scientific review of how marijuana is scheduled under federal law. After receiving HHS’s recommendations last August, the attorney general sought the legal advice of the Justice Department’s Office of Legal Counsel (‘OLC’) on questions relevant to this rulemaking. In light of HHS’s medical and scientific determinations, and OLC’s legal advice, the attorney general exercised his authority under the law to initiate the rulemaking process to transfer marijuana to Schedule 3.”

The process to make the change includes several steps, including a public comment period and final judicial review. “Still, the reclassification of cannabis would mark a new era in America’s often contradictory relationship with a substance already legalized in one form or another in more than half the states,” stated an article in The Week (https://cnw.fm/3pLq1).

The Week noted that perhaps the most significant change reclassification would bring would be increasing governmental ability to conduct further research into the health benefits of cannabis. The article stated that “reclassification also means the government acknowledges cannabis, like all other Schedule 3 substances, has an ‘accepted medical use and may lawfully be dispensed by prescription,’ the Congressional Research Service said. However, any such prescriptions must be approved by the Food and Drug Administration.

“Beyond expanding and easing access to federal research opportunities, reclassifying cannabis will have a major impact on the booming — but still legally murky — marijuana industry as a whole,” the article observed.

With these looming changes as a backdrop, MedCana’s commitment to building the technology, laboratories, growing facilities and scientific teams needed to provide premium pharmaceutical-grade cannabis extracts to the world is perfectly timed. Committed to absolute integrity, sustainability and social responsibility, MedCana is a holding company focused on developing companies in the agricultural-technology and the cannabis industries. As MedCana moves forward with its expansion plans, the company remains committed to delivering on its promise of building a solid foundation for future growth of its holdings.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://cnw.fm/SFWJ

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Feds Outline Research Priorities on Cannabinoids, Medical Marijuana

Health officials at the federal level have outlined research priorities on cannabinoids and cannabis in a new report by the National Center for Complementary and Integrative Health (NCCIH). The report highlights efforts by the NCCIH and other National Institutes of Health (NIH) entities to bridge the gap between the medicinal use of cannabis and the research informing its efficacy and safety.

Key areas of research include the effects of cannabis on social anxiety, pain and sleep; the use of terpenes therapeutically; the use of computers to identify bioactive minor cannabinoids in hemp; and the chemical synthesis of uncommon cannabinoids.

Funding opportunities were introduced by NCCIH in 2019, and $3 million in grants was awarded to researchers to investigate the mechanisms of action and possible pain-relieving properties of phytochemicals found in cannabis. This initiative included minor cannabinoids, excluding delta 9 THC, and terpenes.

Over the years, research has expanded to cover several key areas, including investigating the impact of CBD on arthritis-related chronic pain; determining the effects of uncommon cannabinoids on microglia; investigating the role of terpenoid and CBD interactions in the control of pain states by the amygdala; and testing terpenes and cannabinoids separately and in combination for morphine-induced pain alleviation in mouse models, among others.

In addition to advancing scientific studies, NIH is supporting the creation of a Resource Center for Cannabinoid and Cannabis Research. The center aims to assist researchers in overcoming barriers and challenges, both scientific and legal, which stand in the way of studying marijuana and its components.

Funding for the center will come from a $1 million allocation from NCCIH in the fiscal year 2025, with cofunding from NCI, NIA and NIDA totaling $100,000 each. Additionally, NCI recently awarded researchers $3.2 million to study the effects of marijuana use during immunotherapy for cancer treatment.

The agency’s website compiles information about the NIH cannabinoid and cannabis research program, including pertinent staff contacts, funding opportunities, priorities and access to research grant applications that are currently being financed.

NCCIH representatives, along with representatives from other federal health entities, convened recently to deliberate on the present status of cannabis research and policy implications for researchers examining cannabis while it remains illegal. The discussion focused on terpenes and cannabinoids’ potential to alleviate pain.

Craig Hopp, deputy director of NCCIH’s extramural research unit and coauthor of the new paper, discussed the U.S. Department of Justice’s recent proposal to reclassify cannabis under the Controlled Substance Act from Schedule 1 to 3, describing it as the elephant in the room for researchers.

While cannabis advocates and researchers have emphasized the potential for a Schedule 3 reclassification to reduce research obstacles related to Schedule 1 substances, Hopp stated that nothing has changed yet in the early phases of the regulation process. He further noted that any modifications won’t happen for at least a year and that it’s still unclear if a Schedule 3 status will eventually enable academics to obtain marijuana for research purposes from state-licensed dispensaries.

Notwithstanding the difficulties in researching restricted substances, the burgeoning legalization movement has coincided with a rise in research. Over the past 10 years, academics have published more than 32,000 studies on marijuana, with recent years setting records for study, according to NORML.

As more marijuana studies are published, they could help companies in the industry such as Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) to keep tweaking their offerings in order to better address the needs of their customers, especially those using medical marijuana products.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Golden Triangle Ventures Inc. (GTVH), Lavish Entertainment Report on Progress of One-of-a-Kind Entertainment Destination

New project “set to transform luxury entertainment and hospitality,” according to company officials
Critical development has included work on infrastructure and improvements
Officials also focused on obtaining required permits, assembling key leadership and identifying ideal vendors

A luxury destination featuring world-class entertainment, opulent accommodations and immersive experiences is rising in the Mojave Desert. The unique property, called Destino Ranch, is a bold, visionary project envisioned by Golden Triangle Ventures (OTC: GTVH) and its wholly owned subsidiary, Lavish Entertainment.

Golden Triangle and Lavish Entertainment recently provided an update (https://cnw.fm/Rfq7n) on the one-of-a-kind project, which is “set to transform luxury entertainment and hospitality.” According to the report, “Upon taking possession of the nearly 70-acre ranch and its overall infrastructure, which included 643 trees, only 35% of the irrigation system was properly functional while most watering was done using a water truck. Today, 98% of the irrigation system is now operational following a massive overhaul.

“Key improvements include replacing and updating 95% of all control valves, re-energizing all existing waterlines and making numerous major system enhancements,” the report continued. “The extensive cleanup efforts have also included the repair of perimeter fencing, reinstallation of gates and opening of roadways around the project.”

The report noted that improvements in the water supply system, such as updating lines and control valves to the storage system and revamping the well system, have been made. In addition, substantial effort has gone into caring for the ranch’s trees, which contributes significantly to the way the property looks.

“Tree care has been a primary focus, involving pruning and trimming for health benefits and ongoing fruit production,” the company reports. “All dead trees have been removed, and new planting is planned to further enhance the project by adding additional fruit trees and various ornamental shade trees. Plans include adding numerous colorful trees and plants to create a park-like atmosphere, improving the environment and enhancing the overall aesthetic appeal of Destino Ranch.”

Along with efforts made on the actual property, company officials are focused on logistics, working closely with city planners and council members to obtain required permits and approvals for the project. “This comprehensive effort encompasses the creation of detailed development and engineering plans, alongside strategizing the acquisition of additional property essential for the project’s completion,” the report noted. “The company is actively engaged in future concept planning to ensure long-term success.”

Finally, a key part of Destino Ranch’s success will depend on management. Lavish Entertainment is dedicated to assembling an experienced, professional board of team members and directors along with identifying key vendors and determining specific site placements. Plans call for the development of a detailed site map to guide the progress of Destino Ranch.

A multifaceted consulting company, Golden Triangle Ventures operates as a parent business pursuing ventures in the health, entertainment and technology sectors. The company is looking to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors the company aims to do business in.

For more information, visit the company’s website at www.GoldenTriangleInc.com.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://cnw.fm/GTVH

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Replicate Results from First GLP-1 Study Following CRO Contract Award for 12-Week Chronic Human Study

Lexaria, a global innovator in drug delivery platforms, recently hired a contract research organization (“CRO”) for its upcoming chronic human study, GLP-1-H24-4
This study will seek to evaluate various glucagon-like peptide-1 (“GLP-1”) formulations, processed with the company’s patented DehydraTECH(TM) technology
The study will feature five arms, with each conducted using several investigational sites in Australia

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the hiring of a contract research organization (“CRO”) that will be responsible for overseeing the execution of the company’s upcoming chronic human study, GLP-1-H24-4. This 12-week study will seek to evaluate various glucagon-like peptide 1 (“GLP-1”) formulations processed with the company’s patented DehydraTECH(TM) technology, which has demonstrated enhanced bioavailability in multiple studies. It will also explore other treatments with efficacy objectives, including, but not limited to, blood sugar reduction and weight loss (https://cnw.fm/dCDXV).

“This study will be the most comprehensive and impactful GLP-1 investigation that Lexaria has ever undertaken,” noted John Docherty, Lexaria’s President.

“The greatly expanded scope compared to our previous studies will allow us to investigate DehydraTECH-GLP-1 safety and efficacy over an extended treatment duration to significantly broaden our knowledge of DehydraTECH’s ability to potentially improve the effectiveness and tolerability of this world-leading class of drugs,” he added.

This study will have five active treatment arms, each with 16 diabetic patients. The first arm will use Rybelsus(R) as a positive control; the second will utilize DehydraTECH-CBD, the third will feature DehydraTECH-semaglutide while the fourth will see a combination of DehydraTECH-CBD and DehydraTECH-semaglutide. The last arm will feature DehydraTECH-tirzepatide. Each patient will be dosed orally daily, subject to change once the final protocol is complete.

Each of these arms of the study will be conducted using several investigational sites in Australia as a registrational Phase 1b study within Australian clinical regulatory authority regulations. Once completed, the study is expected to be equally regarded as a Phase 1b registrational study by the U.S. Food and Drug Administration (“FDA”).

For Lexaria, this marks a significant milestone in its quest to offer a viable treatment option for diabetes. In 2022, its DIAB-A22-1 multi-week rodent study utilizing DehydraTECH-CBD demonstrated weight loss of 7% and reduced blood glucose levels of 19.9%+/-7%. In January 2024, the company discovered that DehydraTECH processing of Rybelsus(R)-branded semaglutide, after a single dose, improved blood sugar control and reached higher levels of semaglutide measured in blood than did Rybelsus(R) itself. The company looks to establish whether this improved pharmacokinetic performance could lead to improved weight loss and/or blood-sugar control compared to Rybelsus(R) alone after multi-week dosing.

Study preparations with the CRO are already in the works pursuant to an initial start-up agreement under which several activities will occur, such as full clinical protocol design and writing in consultation with medical experts, regulatory authority submissions, and data management planning. Lexaria’s management is optimistic that the results from this undertaking will be positive, further exemplifying the potential of its DehydraTECH technology and showcasing its overall viability in the potential treatment of diabetes and weight loss.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com